433 related articles for article (PubMed ID: 19344187)
1. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
2. Toxin-labeled monoclonal antibodies.
Kreitman RJ
Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
[TBL] [Abstract][Full Text] [Related]
3. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
4. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman RJ
Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336
[TBL] [Abstract][Full Text] [Related]
5. Recombinant toxins for the treatment of cancer.
Kreitman RJ
Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
[TBL] [Abstract][Full Text] [Related]
6. Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ; Pastan I
Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
12. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
[TBL] [Abstract][Full Text] [Related]
13. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxins for the treatment of haematological malignancies.
Kreitman RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1115-28. PubMed ID: 15268678
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
17. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
18. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
19. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
